企業プロフィール
Biofrontera Inc 株価・ニュース・カタリスト
- ティッカー:
- BFRI
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
1.35 USD (+3.85%)
終値
最終更新: 2026年8月17日
13.2M USD
時価総額
株価変動の要因
As of Aug 17, 2026, BFRI closed up 3.85% at $1.35. No new same-company headline was identified in the current news window.
企業概要
Dermatology Photodynamic Therapy
Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines Ameluz, a topical photosensitizer, with the RhodoLED illumination system.
Actinic Keratosis Franchise
Ameluz is established in actinic keratosis and is being developed for broader treatment fields and additional body locations. The company is also pursuing superficial basal cell carcinoma and acne to expand the platform.
U.S. Commercial Infrastructure
Biofrontera operates a specialist dermatology sales organization and has restructured its economics with Biofrontera AG to retain a larger share of product value.
今後のカタリスト
- FDA action on the Ameluz supplemental application for superficial basal-cell carcinoma in late September 2026.
- Potential U.S. launch of Ameluz in superficial basal-cell carcinoma in the first quarter of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。